CARGO Therapeutics, Inc.

CARGO Therapeutics, Inc. (NASDAQ: CRGX) related to its sale to Concentra Biosciences, LLC for $4.379 in cash per CARGO share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of CARGO in excess of $217.5 million; and (ii) 80% of the net proceeds from the sale, license, or other disposition of either (a) CRG-022, a CDRR CAR T-cell therapy, or (b) CRG-023, a CD19/CD20/CD22 tri-specific CAR T therapy, or (c) the Allogeneic Platform, that occurs within 2 years following the closing.

The investigation is focused on whether the process and price are fair. To receive more information regarding the investigation of CARGO Therapeutics, Inc. please fill out the form below.

To start a Class Action lawsuit, please sign the CARGO Therapeutics, Inc. Retainer Agreement

This confirms that you have retained Monteverde & Associates PC to pursue claims on your behalf and/or file a class action against the CARGO Therapeutics, Inc. and/or its board of directors or officers with you as a named plaintiff and on a fully contingent basis with respect to our fees. Further, you purchased the shares prior to the announcement of the corporate action sought by the board of directors for CARGO Therapeutics, Inc. and you did not buy said shares to commence any legal action. Furthermore, you must preserve all documents and communications related to CARGO Therapeutics, Inc..

We agree to advance all expenses in the litigation, which means that you are not liable or responsible to pay any of the expenses of the action, whether attorneys’ fees or costs. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees or costs. Should we obtain a favorable result, you authorize us to explore a release of all claims, and ask the court to award us compensation up to one-third of any monetary class fund plus expenses, or to negotiate a mootness fee with the company or defendants, but, we will never ask you to pay any of the fees or costs.

As the client you are entitled to direct the litigation in any way you deem proper, and may at any time order us to dismiss the case or opt-out. Should you choose to do so, we will never ask you to reimburse us directly for any legal fees or expenses. During the course of this litigation, you authorize us to employ, share work and/or fees with other attorneys or law firms to prosecute your case.  Further, the file compiled in the case constitutes the work product and property of this firm over which the firm has complete control with respect to its use and/or disclosure.

We look forward to representing you in this case.

Juan E. Monteverde, Esq.

AGREED: Sign Name

Signed pursuant to California Civil Code Section 1633. 1, et seq. – Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of Signing: 08/29/2026